Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.42 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.42 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4681128 | 0.98 | KMT2A (0.47) | KMT2AMEN1NPSR1SMN1; SMN2MAPK1 | |
| SCHEMBL27694192 | 0.88 | MEN1 (0.50) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4678826 | 0.85 | GRIN2B (0.52) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL148277 | 0.85 | SCN5A (0.50) | KMT2AMEN1NPSR1SMN1; SMN2MAPK1 | |
| SCHEMBL542709 | 0.85 | GRIN2B (0.52) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL542683 | 0.85 | MEN1 (0.58) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL27675677 | 0.85 | SMN1; SMN2 (0.48) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL542958 | 0.85 | PIM1 (0.44) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3889285 | 0.84 | MEN1 (0.66) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3778880 | 0.84 | MEN1 (0.66) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414330-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | Merck Patent GmbH (DE) | 2012-02-08 | — | — | EP | claimed |
| WO-2010115491-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-14 | — | — | WO | claimed |
| EP-3952914-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | Ranok Therapeutics (Hangzhou) Co. Ltd. (CN) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020207396-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2020-10-15 | — | — | WO | disclosed |
| EP-2414330-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | Merck Patent GmbH (DE) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010115491-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| CN-1277824-C | Piperazine derivatives | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | CN | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| CN-1533382-A | Piperazine derivatives | - | 2004-09-29 | — | — | CN | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | KMT2A 1046/4885MEN1 1694/4885NPSR1 80/4885 |
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | KMT2A 1046/4885MEN1 1694/4885NPSR1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.